$2 million gene therapy cures require a financing model
-
By
-
William V. Padula
-
June 8, 2026
-
Clinical Scorecard: Financing Strategies Needed for $2 Million Gene Therapy Cures
At a Glance
| Category | Detail |
|---|
| Condition | Gene therapy for diseases like sickle cell |
| Key Mechanisms | Single treatment with potential long-term value |
| Target Population | Patients eligible for high-cost gene therapies |
| Care Setting | Medicaid and private insurance systems |
Key Highlights
- Gene therapies can cure diseases with a single treatment but cost $2 million or more.
- Current healthcare financing models struggle to accommodate large upfront costs.
- The Cell and Gene Therapy Access Model aims to improve access through outcomes-based payment.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients eligible for gene therapies, particularly in Medicaid
Access to therapies is limited by financing and delivery systems.
Clinical Best Practices
Related Resources & Content
